ORIC Pharmaceuticals Advances Lead Candidates to Phase 3, Secures $59.9M via ATM, Extends Cash Runway

summarizeSummary

ORIC Pharmaceuticals announced positive Phase 1b data for rinzimetostat and enozertinib, with rinzimetostat advancing to Phase 3. The company also raised $59.9 million through an ATM offering, extending its cash runway into 2H 2028.

check_boxKey Events

• Rinzimetostat Advances to Phase 3

  The company selected 400 mg QD rinzimetostat in combination with darolutamide as the Recommended Phase 3 Dose (RP3D) for metastatic castration-resistant prostate cancer (mCRPC) and plans to initiate the global Phase 3 'Himalayas-1' trial. Phase 1b data showed an 84% 5-month radiographic progression-free survival (rPFS) and a differentiated safety profile.

• Enozertinib Shows Strong Phase 1b Data

  Additional Phase 1b data for enozertinib in NSCLC patients with EGFR exon 20 insertion and atypical mutations demonstrated competitive systemic response rates and profound anti-tumor activity in the CNS, with 80 mg QD selected as the monotherapy dose for potential Phase 3 development.

• Successful ATM Offering Extends Cash Runway

  Oric Pharmaceuticals raised $59.9 million in net proceeds during Q1 2026 through its at-the-market (ATM) offering, selling 4,698,400 shares at a weighted average price of $12.96. This financing extends the company's cash, cash equivalents, and investments to fund operations into the second half of 2028.

• Increased R&D Investment

  Research and development expenses increased to $31.4 million in Q1 2026 from $24.6 million in Q1 2025, primarily driven by the advancement of rinzimetostat and enozertinib programs.

auto_awesomeAnalysis

Oric Pharmaceuticals reported significant clinical advancements for its lead candidates, rinzimetostat and enozertinib, alongside a substantial capital raise that extends its cash runway. The selection of rinzimetostat's Recommended Phase 3 Dose (RP3D) and plans to initiate a global Phase 3 trial are critical milestones, supported by strong Phase 1b data showing an 84% radiographic progression-free survival (rPFS) and a favorable safety profile. Similarly, enozertinib demonstrated competitive systemic and intracranial activity in Phase 1b, with a monotherapy dose selected for potential Phase 3 development. These clinical successes are bolstered by the company's successful at-the-market (ATM) offering, which raised $59.9 million in net proceeds during Q1 2026, extending the cash runway into the second half of 2028. While the net loss increased, this is largely attributable to increased research and development investments necessary to advance these programs. This filing adds detailed financial and clinical specifics to prior disclosures made on the same day.